NO20062992L - Nye M3 muskarine acetykolinreseptorantagonister - Google Patents

Nye M3 muskarine acetykolinreseptorantagonister

Info

Publication number
NO20062992L
NO20062992L NO20062992A NO20062992A NO20062992L NO 20062992 L NO20062992 L NO 20062992L NO 20062992 A NO20062992 A NO 20062992A NO 20062992 A NO20062992 A NO 20062992A NO 20062992 L NO20062992 L NO 20062992L
Authority
NO
Norway
Prior art keywords
muscarinic
receptor antagonists
acetykoline
new
methods
Prior art date
Application number
NO20062992A
Other languages
English (en)
Norwegian (no)
Inventor
Jakob Busch-Petersen
Michael R Palovich
Jian Jin
Wei Fu
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34676665&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20062992(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20062992L publication Critical patent/NO20062992L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
NO20062992A 2003-12-03 2006-06-27 Nye M3 muskarine acetykolinreseptorantagonister NO20062992L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52682403P 2003-12-03 2003-12-03
PCT/US2004/040667 WO2005055940A2 (en) 2003-12-03 2004-12-03 Novel m3 muscarinic acetylcholine receptor antagonists

Publications (1)

Publication Number Publication Date
NO20062992L true NO20062992L (no) 2006-06-27

Family

ID=34676665

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062992A NO20062992L (no) 2003-12-03 2006-06-27 Nye M3 muskarine acetykolinreseptorantagonister

Country Status (17)

Country Link
US (1) US20070179184A1 (pt)
EP (1) EP1708702A2 (pt)
JP (1) JP2007513181A (pt)
KR (1) KR20060123415A (pt)
AR (1) AR046784A1 (pt)
AU (1) AU2004296207A1 (pt)
BR (1) BRPI0417215A (pt)
CA (1) CA2549272A1 (pt)
IL (1) IL175995A0 (pt)
IS (1) IS8515A (pt)
MA (1) MA28217A1 (pt)
MX (1) MXPA06006372A (pt)
NO (1) NO20062992L (pt)
PE (1) PE20050897A1 (pt)
UY (1) UY28645A1 (pt)
WO (1) WO2005055940A2 (pt)
ZA (1) ZA200604395B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200519108A (en) * 2003-07-17 2005-06-16 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
MXPA06004242A (es) * 2003-10-17 2006-06-28 Glaxo Group Ltd Antagonistas del receptor muscarinico de la acetilcolina.
TW200524577A (en) * 2003-11-04 2005-08-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
WO2005087236A1 (en) * 2004-03-11 2005-09-22 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
WO2005095407A1 (en) * 2004-03-17 2005-10-13 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
WO2005094251A2 (en) * 2004-03-17 2005-10-13 Glaxo Group Limited M3muscarinic acetylcholine receptor antagonists
AR050902A1 (es) 2004-04-27 2006-12-06 Glaxo Group Ltd Compuesto de quinuclidina, composicion farmaceutica que lo comprende y su usopara preparar dicha composicion
EP1747219A4 (en) * 2004-05-13 2010-05-26 Glaxo Group Ltd Antagonists of muscarinic acetylcholine receptor
EA200700243A1 (ru) 2004-07-14 2007-08-31 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы лечения гепатита с
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
EP1781289A1 (en) 2004-07-22 2007-05-09 PTC Therapeutics, Inc. Thienopyridines for treating hepatitis c
EA200700251A1 (ru) * 2004-08-10 2007-08-31 Инсайт Корпорейшн Амидосоединения и их применение в качестве фармацевтических средств
JP2008520579A (ja) * 2004-11-15 2008-06-19 グラクソ グループ リミテッド 新規m3ムスカリン性アセチルコリン受容体アンタゴニスト
EP1937267A4 (en) * 2005-08-02 2009-08-26 Glaxo Group Ltd M3-MUSCARIN ACETYLCHOLIN RECEPTOR ANTAGONISTS
US7767691B2 (en) * 2005-08-18 2010-08-03 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists containing an azoniabiocyclo[2.2.1] heptane ring system
CL2009000249A1 (es) 2008-02-06 2009-09-11 Glaxo Group Ltd Compuestos derivados de pirazolo[3,4-b] piridin-butanodiamida; composicion farmaceutica; y su uso en el tratamiento del asma, enfermedad pulmonar obstructiva cronica, rinitis, dermatitis atopica, psoriasis.
AR070564A1 (es) 2008-02-06 2010-04-21 Glaxo Group Ltd Derivados de 1h-pirazolo[3,4-b]piridin-5-ilo,inhibidores de fosfodiesterasas pde4 y antagonistas de receptores muscarinicos de acetilcolina(machr), utiles en el tratamiento y/o profilaxis de enfermedades respiratorias y alergicas,y composiciones farmaceuticas que los comprenden
UY31637A1 (es) 2008-02-06 2009-08-03 Farmacoforos duales-antagonistas muscarinicos de pde4
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232978A (en) * 1988-12-23 1993-08-03 Merck Patent Gesellschaft Mit Beschrankter Haftung 1-(2-arylethyl)-pyrrolidines
AU4710199A (en) * 1998-06-22 2000-01-10 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
US6420364B1 (en) * 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases

Also Published As

Publication number Publication date
IS8515A (is) 2006-06-19
MXPA06006372A (es) 2006-08-23
KR20060123415A (ko) 2006-12-01
PE20050897A1 (es) 2005-11-06
IL175995A0 (en) 2006-10-05
ZA200604395B (en) 2007-10-31
WO2005055940A3 (en) 2005-09-15
CA2549272A1 (en) 2005-06-23
UY28645A1 (es) 2005-06-30
AU2004296207A1 (en) 2005-06-23
AR046784A1 (es) 2005-12-21
US20070179184A1 (en) 2007-08-02
JP2007513181A (ja) 2007-05-24
MA28217A1 (fr) 2006-10-02
EP1708702A2 (en) 2006-10-11
BRPI0417215A (pt) 2007-02-21
WO2005055940A2 (en) 2005-06-23

Similar Documents

Publication Publication Date Title
NO20062042L (no) Muskariniske acetylkolin reseptorantangonister
NO20063032L (no) Nye M3 muskarinacetylkolinreceptorantagoniser
NO20065417L (no) Muskarine acetylkolinreceptorantagonister
UY27927A1 (es) Antagonistas del receptor muscarínico m3 de acetilcolina
CY1113295T1 (el) Ανταγωνιστες m3 μουσκαρινικου υποδοχεα ακετυλοχολινης
NO20060777L (no) Muskarine acetylkolinreseptorantagonister
TW200600093A (en) M3 muscarinic acetylcholine receptor antagonists
BRPI0417215A (pt) antagonistas de receptor muscarìnico de acetilcolina m3
NO20060776L (no) Muskarine acetylkolinreseptorantagonister
NO20060775L (no) Muskarine acetylkolinreseptorantagonister
NO20062071L (no) Muskariniske acetylkolin-reseptorantangonister
BRPI0506777A (pt) antagonistas do receptor muscarìnico da acetilcolina
WO2006055553A3 (en) Novel m3 muscarinic acetylcholine receptor antagonists
TW200600500A (en) M3 muscarinic acetylcholine receptor antagonists
WO2006055503A3 (en) Novel m3 muscarinic acetylcholine receptor antagonists
TW200606161A (en) Muscarinic acetylcholine receptor antagonists
WO2007016639A3 (en) M3 muscarinic acetylcholine receptor antagonists
WO2005086873A3 (en) Novel m3 muscarinic acetylcholine receptor antagonists

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application